Our Mission: Innovating to Protect Humanity from the Global Threat of Antimicrobial Resistance: Integrating Solutions Across Human and Veterinary Medicine, Stewardship, and Awareness
Dedication of the Stuart B. Levy CIMAR at Tufts
September 21, 2020
CIMAR is now known as the Stuart B. Levy Center for Integrated Management of Antimicrobial Resistance at Tufts (or simply, the Levy CIMAR). Friends, family, and colleagues from all over came together via Zoom on Friday to celebrate this event with Dr. Levy’s family and members of our Senior Leadership.
During his more than four decades at Tufts University and Tufts Medical Center, Dr. Levy led the paradigm shift in how we view antibiotic use and stewardship. In his work on mechanisms of antibiotic resistance and spread of resistance determinants among microbes, his was the first voice of warning of the dangers of antibiotic overuse in the emergence of drug resistance. His famous study showing that antibiotic resistance elements can be transferred from intestinal flora of farm animals to workers was a breakthrough (NEJM, 1976). It demonstrated that the use of antibiotics as livestock growth-enhancers was a dangerous practice with obvious risks to clinical care.
Dr. Levy’s pioneering work in fighting antibiotic misuse and resistance was a key inspiration behind CIMAR when we launched in late 2018, and we are pleased to now be named in his honor. You can more about Dr. Levy’s life and work on our website. A video of the September 18th event follows below.
Introducing Levy CIMAR Executive Director Brian Noonan
September 23, 2020
We are excited to announce that Dr. Brian Noonan has taken on the role of Executive Director at the Levy CIMAR! Dr. Noonan is an experienced leader of interdisciplinary research teams both in academia and industry. He will work closely with our faculty to develop grant proposals and will be in charge of our outreach to pharma and philanthropy.
Dr. Noonan’s research interests include the discovery of vaccines and anti-microbial agents targeting important pathogens and the use of immunomodulatory biologics to control cytokine induction in sepsis. You can learn more about him on our Leadership page.
